Michael A Fink
Overview
Explore the profile of Michael A Fink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weinberg L, Caragata R, Hazard R, Ludski J, Lee D, Slifirski H, et al.
PLoS One
. 2024 May;
19(5):e0303631.
PMID: 38820491
Background: Very little information is currently available on the use and outcomes of venovenous bypass (VVB) in liver transplantation (LT) in adults in Australia. In this study, we explored the...
2.
Mikhail R, McKay S, Fink M
Transplant Direct
. 2023 Dec;
10(1):e1569.
PMID: 38111838
No abstract available.
3.
Fink M, Gow P, McCaughan G, Hodgkinson P, Chen J, McCall J, et al.
Clin Transplant
. 2023 Dec;
38(1):e15203.
PMID: 38088459
Patients with high model for end-stage liver disease (MELD) scores waiting for liver transplantation in Australia and New Zealand (ANZ) have had limited access to deceased donor livers and therefore...
4.
Janko N, Majeed A, Clements W, Fink M, Lubel J, Goodwin M, et al.
Hepatol Commun
. 2023 Apr;
7(5).
PMID: 37102761
Background And Aims: Recent guidelines recognize the limitations of standard coagulation tests in predicting bleeding and guiding pre-procedural blood component prophylaxis in cirrhosis. It is unclear whether these recommendations are...
5.
Lee E, Perini M, Makalic E, Oniscu G, Fink M
Prog Transplant
. 2022 Dec;
33(1):25-33.
PMID: 36537129
In Australia and New Zealand, liver allocation is needs based (based on model for end-stage liver disease score). An alternative allocation system is a transplant benefit-based model. Transplant benefit is...
6.
Barreto S, Strasser S, McCaughan G, Fink M, Jones R, McCall J, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681757
Background: Expansion in liver transplantation (LT) criteria for HCC from Milan to UCSF has not adversely impacted overall survival, prompting further expansion towards Metroticket 2.0 (MT2). In this study, we...
7.
Howell J, Majumdar A, Fink M, Byrne M, McCaughan G, Strasser S, et al.
Liver Transpl
. 2021 Oct;
28(2):236-246.
PMID: 34624175
Introduction of universal access to direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in Australia and New Zealand on March 1 , 2016, has had a major impact on...
8.
Privett B, Perini M, Weinberg L, Fink M, Muralidharan V, Lee E, et al.
ANZ J Surg
. 2021 Sep;
91(11):2459-2465.
PMID: 34514684
Background: Postoperative pancreatic fistula (POPF) remains a significant cause of morbidity in patients undergoing distal pancreatectomy (DP). The use of polyethylene glycol (PEG) and recombinant human albumin sealant gel applied...
9.
Cox D, Fong J, Liew C, Goh S, Yeoh M, Fink M, et al.
ANZ J Surg
. 2018 Nov;
88(12):1337-1342.
PMID: 30414227
Background: Acute biliary pain is the most common presentation of gallstone disease. Untreated patients risk recurrent pain, cholecystitis, obstructive jaundice, pancreatitis and multiple hospital presentations. We examine the outcome of...
10.
Roberts S, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, et al.
Scand J Gastroenterol
. 2018 Nov;
53(10-11):1368-1375.
PMID: 30394145
Objective: The objectives of our study were firstly to characterize the treatment stage migration phenomenon in early (Barcelona Clinic Liver Cancer [BCLC]-0/A) stage hepatocellular carcinoma (HCC) by comparing the efficacy...